Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Retinal thinning differentiates treatment effects in relapsing multiple sclerosis below the clinical threshold.
Bsteh G, Hegen H, Krajnc N, Föttinger F, Altmann P, Auer M, Berek K, Kornek B, Leutmezer F, Macher S, Monschein T, Ponleitner M, Rommer P, Schmied C, Zebenholzer K, Zulehner G, Zrzavy T, Deisenhammer F, Di Pauli F, Pemp B, Berger T. Bsteh G, et al. Among authors: monschein t. Ann Clin Transl Neurol. 2024 Dec 16. doi: 10.1002/acn3.52279. Online ahead of print. Ann Clin Transl Neurol. 2024. PMID: 39686570 Free article.
Retinal layer thinning for monitoring disease-modifying treatment in relapsing multiple sclerosis-Evidence for applying a rebaselining concept.
Bsteh G, Hegen H, Krajnc N, Föttinger F, Altmann P, Auer M, Berek K, Kornek B, Leutmezer F, Macher S, Monschein T, Ponleitner M, Rommer P, Schmied C, Zebenholzer K, Zulehner G, Zrzavy T, Deisenhammer F, Di Pauli F, Pemp B, Berger T. Bsteh G, et al. Among authors: monschein t. Mult Scler. 2024 Aug;30(9):1128-1138. doi: 10.1177/13524585241267257. Epub 2024 Aug 7. Mult Scler. 2024. PMID: 39109593 Free article.
Immunophenotyping in routine clinical practice for predicting treatment response and adverse events in patients with MS.
Zrzavy T, Rieder K, Wuketich V, Thalhammer R, Haslacher H, Altmann P, Kornek B, Krajnc N, Monschein T, Schmied C, Zebenholzer K, Zulehner G, Berger T, Rommer P, Leutmezer F, Bsteh G. Zrzavy T, et al. Among authors: monschein t. Front Neurol. 2024 Apr 16;15:1388941. doi: 10.3389/fneur.2024.1388941. eCollection 2024. Front Neurol. 2024. PMID: 38689880 Free PMC article.
Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).
Monschein T, Dekany S, Zrzavy T, Ponleitner M, Altmann P, Bsteh G, Kornek B, Rommer P, Enzinger C, Di Pauli F, Kraus J, Berger T, Leutmezer F, Guger M; Austrian MS Treatment Registry (AMSTR). Monschein T, et al. J Neurol. 2023 Aug;270(8):3787. doi: 10.1007/s00415-023-11784-1. J Neurol. 2023. PMID: 37272963 Free PMC article. No abstract available.
Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).
Monschein T, Dekany S, Zrzavy T, Ponleitner M, Altmann P, Bsteh G, Kornek B, Rommer P, Enzinger C, Di Pauli F, Kraus J, Berger T, Leutmezer F, Guger M; Austrian MS Treatment Registry (AMSTR). Monschein T, et al. J Neurol. 2023 Aug;270(8):3779-3786. doi: 10.1007/s00415-023-11686-2. Epub 2023 Apr 19. J Neurol. 2023. PMID: 37074388 Free PMC article.
19 results